A Landmark Device. And a Turning Point for PFO Closure.

The Amplatzer™ PFO Occluder set the standard, pioneering treatment with a device developed specifically for PFO closure. It’s the leading PFO closure device to date, with over 130,000 devices implanted worldwide.4

Amplatzer PFO Occluder

Four published clinical trials provide conclusive evidence of the superiority of Patent Foramen Ovale (PFO) closure in reducing the risk of recurrent stroke compared with medical management.1-4 The RESPECT trial, the largest trial with the most extensive patient follow-up, demonstrated an excellent safety profile while significantly reducing the risk of recurrent stroke:1

Highlights from the RESPECT trial1

  • The most extensive patient follow-up with 5,810 patient years of data
  • Zero device erosions, thrombus, or embolization events
  • 94.2% effective closure rates at 6 months
  • Only trial to include patients on anticoagulation therapy

Comments from RESPECT Trial Principal Investigator

Jeffrey Saver, MD discusses the data supporting the benefits of PFO closure.

RESPECT Trial: A Turning Point in PFO Closure

The RESPECT trial is notable for demonstrating that the Amplatzer PFO Occluder is more beneficial than medical therapy alone in preventing recurrent stroke.1

The findings also revealed a reduction in the risk of recurrent cryptogenic stroke with the use of the Amplatzer PFO Occluder:1

Relative Risk Reduction for Recurrent Cryptogenic Stroke: 62%

Amplatzer PFO relative risk reduction for recurrent cryptogenic stroke

Relative Risk Reduction for any Recurrent Ischemic Stroke: 45%

Amplatzer PFO relative risk reduction for any recurrent ishemic stroke

The trial analysis reveals that the device reduced recurrent ischemic stroke by eliminating a conduit through which venous source emboli can travel to the brain.

Low Rate of Serious Adverse Events

RESPECT data further revealed low rates of serious adverse events:1

  • 0% Device Embolization
  • 0% Device Erosion
  • 0% Device Thrombus

Excellent Procedural Results

In the RESPECT Trial, the device demonstrated high rates of technical and procedural success and achieved excellent effective closure with highly stringent criteria.

  • 99.1% Technical Success
  • 96.1% Procedural Success
  • 94.2% Effective closure at 6 months (n <= 9 bubbles)

Prioritizing Prevention

Referring physicians, and particularly neurologists who provide the primary point of care for patients who've had an ischemic stroke, may consider these factors in treatment planning:

  • Is the stroke cryptogenic?
    Rule out known causes
  • Is the patient a good candidate for alternative therapy?
    Consider the patient’s age and medical history
  • Is there a possibility of a PFO?
    Determine the likelihood of paradoxical embolism

A cardiologist can then determine whether a PFO is present and can help define treatment options.

Leadership in PFO Closure Treatment

The Amplatzer PFO Occluder’s unique design is a primary reason for its safety and efficacy.

In addition, the occluder’s capability to be fully recaptured and fully repositioned allows physicians to confirm proper placement prior to final release of the device.

Amplatzer PFO Design

Learn more about Amplatzer™ PFO Occluder by visiting the Abbott Structural Heart website.

Ordering Information

Amplatzer™ PFO Occluder
Model/Reorder Number Right Atrial Disc Diameter
Left Atrial Disc Diameter
Minimum Recommended Sheath Size
9-PFO-018 18 mm 18 mm 8 F; 45° curve
9-PFO-025 25 mm 18 mm 8 F; 45° curve
9-PFO-035 35 mm 25 mm 9 F; 45° curve
Amplatzer PFO
Amplatzer Trevisio™ Intravascular Delivery System
Model/Reorder Number Sheath Size Tip Angle Sheath Inner Diameter Sheath Outer Diameter Usable Length
9-ATV08F45/80 8 F 45° 2.69 mm/0.11 inch 3.45 mm/0.14 inch 80 cm
9-ATV09F45/80 9 F 45° 3.00 mm/0.12 inch 3.81 mm/0.15 inch 80 cm
Amplatzer TorqVue® 45° Delivery System
9-ITV08F45/80 8 F 45° 2.69 mm/0.11 inch 3.45 mm/0.14 inch 80 cm
9-ITV09F45/80 9 F 45° 3.00 mm/0.12 inch 3.81 mm/0.15 inch 80 cm
Amplatzer Guidewire
Model/Reorder Number Diameter Body Tip Description Usable Length
9-GW-002 0.035 inch Super Stiff 1.55 mm, Modified J-tip 260 cm
Amplatzer TorqVue® Exchange Systems
Ordering Information - Contents: 1 each delivery sheath, dilator, exchange wire, hemostasis valve, loader, and plastic vise
Model/Reorder Number Sheath Size Tip Angle Sheath Inner Diameter Sheath Outer Diameter Usable Length
9-EITV09F45/80 9 F 45° 3.00 mm/0.12 inch 3.81 mm/0.15 inch 80 cm
9-EITV12F45/80 12 F 45° 3.99 mm/0.16 inch 4.80 mm/0.19 inch 80 cm
Shortest Distance from Defect to Aortic Root or Distance from Defect to Superior Vena Cava Orifice (mm) Suggested Amplatzer PFO Occluder size (mm)
Greater than or equal to 17.5 35
15.0-17.4 30
12.5-14.9 25
9-12.4 18
less than 9 Do not implant device


  1. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377:1022-1032. doi: 10.1056/NEJMoa1610057. 
  2. Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017; 377: 1033-1042. doi: 10.1056/NEJMoa1707404.
  3. Mas J-L, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011-1021 and supplementary appendix. doi: 10.1056/NEJMoa1705915.
  4. Lee, Pil Hyung et al. “Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial.” Journal of the American College of Cardiology vol. 71,20 (2018): 2335-2342. doi:10.1016/j.jacc.2018.02.046.
  5. Data on file at Abbott.


    *On commonly used sizes (25 mm and 35 mm devices)  

Important Safety Information

Important Safety Information




The AMPLATZER™ PFO Occluder is indicated for percutaneous transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke.


  • Patients with intra-cardiac mass, vegetation, tumor or thrombus at the intended site of implant, or documented evidence of venous thrombus in the vessels through which access to the PFO is gained.
  • Patients whose vasculature, through which access to the PFO is gained, is inadequate to accommodate the appropriate sheath size.
    Patients with anatomy in which the AMPLATZER™ PFO device size required would interfere with other intracardiac or intravascular structures, such as valves or pulmonary veins.
  • Patients with other source of right-to-left shunts, including an atrial septal defect and/or fenestrated septum.
  • Patients with active endocarditis or other untreated infections.


  • Patients who are at increased risk for venous thromboembolic events should be managed with thromboembolic risk reduction regimen after the PFO Closure following standard of care.
  • Do not use this device if the sterile package is open or damaged.
  • Prepare for situations that require percutaneous or surgical removal of this device. This includes availability of a surgeon.
  • Embolized devices must be removed as they may disrupt critical cardiac functions. Do not remove an embolized occluder through intracardiac structures unless the occluder is fully recaptured inside a catheter or sheath.
  • Patients who are allergic to nickel can have an allergic reaction to this device.
  • This device should be used only by physicians who are trained in standard transcatheter techniques.
  • Transient hemodynamic compromise may be encountered during device placement, which may require fluid replacement or other medications as determined by the physician.
  • Do not release the device from the delivery cable if the device does not conform to its original configuration, or if the device position is unstable or if the device interferes with any adjacent cardiac structure (such as Superior Vena Cava (SVC), Pulmonary Vein (PV), Mitral Valve (MV), Coronary Sinus (CS), aorta (AO)). If the device interferes with an adjacent cardiac structure, recapture the device and redeploy. If still unsatisfactory, recapture the device and either replace with a new device or refer the patient for alternative treatment.
  • Ensure there is sufficient distance from the PFO to the aortic root or SVC (typically defined as 9 mm or greater as measured by echo). See Figure 6. and Figure 7.


  • The safety and effectiveness of the AMPLATZER™ PFO Occluder has not been established in patients (with):
    • Age less than 18 years or greater than 60 years because enrollment in the pivotal study (the RESPECT trial) was limited to patients 18 to 60 years old
    • A hypercoagulable state including those with a positive test for a anticardiolipin antibody (IgG or IgM), Lupus anticoagulant, beta-2 glycoprotein-1 antibodies, or persistently elevated fasting plasma homocysteine despite medical therapy
    • Unable to take antiplatelet therapy
    • Atherosclerosis or other arteriopathy of the intracranial and extracranial vessels associated with a ≥50% luminal stenosis
    • Acute or recent (within 6 months) myocardial infarction or unstable angina
    • Left ventricular aneurysm or akinesis
    • Mitral valve stenosis or severe mitral regurgitation irrespective of etiology
    • Aortic valve stenosis (mean gradient greater than 40 mmHg) or severe aortic valve regurgitation
    • Mitral or aortic valve vegetation or prosthesis
    • Aortic arch plaques protruding greater than 4 mm into the aortic lumen
    • Left ventricular dilated cardiomyopathy with left ventricular ejection fraction (LVEF) less than 35%
    • Chronic, persistent, or paroxysmal atrial fibrillation or atrial flutter
    • Uncontrolled hypertension or uncontrolled diabetes mellitus
    • Diagnosis of lacunar infarct probably due to intrinsic small vessel as qualifying stroke event
    • Arterial dissection as cause of stroke
    • Index stroke of poor outcome (modified Rankin score greater than 3)
    • Pregnancy at the time of implant
    • Multi-organ failure
  • Use on or before the last day of the expiration month that is printed on the product packaging label.
  • This device was sterilized with ethylene oxide and is for single use only. Do not reuse or re-sterilize this device. Attempts to re-sterilize this device can cause a malfunction, insufficient sterilization, or harm to the patient.
  • The AMPLATZER™ PFO Occluder device consists of a nickel-titanium alloy, which is generally considered safe. However, in vitro testing has demonstrated that nickel is released from this device for a minimum of 60 days. Patients who are allergic to nickel may have an allergic reaction to this device, especially those with a history of metal allergies. Certain allergic reactions can be serious; patients should be instructed to notify their physicians immediately if they suspect they are experiencing an allergic reaction such as difficulty breathing or inflammation of the face or throat. Some patients may also develop an allergy to nickel if this device is implanted.
  • Store in a dry place.
  • Pregnancy – Minimize radiation exposure to the fetus and the mother.
  • Nursing mothers – There has been no quantitative assessment for the presence of leachables in breast milk.

Potential adverse events that may occur during or after a procedure using this device may include, but are not limited to: Air embolus Allergic drug reaction; Allergic dye reaction; Allergic metal reaction: Nitinol (nickel, titanium), platinum/iridium, stainless steel (chromium, iron, manganese, molybdenum, nickel); Anesthesia reactions; Apnea; Arrhythmia; Bacterial endocarditis; Bleeding ; Brachial plexus injury; Cardiac perforation; Cardiac tamponade; Cardiac thrombus; Chest pain; Device embolization; Device erosion; Deep vein thrombosis; Death; Endocarditis; Esophagus injury; Fever; Headache/migraine; Hypertension/hypotension; Myocardial infarction; Pacemaker placement secondary to PFO device closure; Palpitations; Pericardial effusion; Pericardial tamponade; Pericarditis; Peripheral embolism; Pleural effusion; Pulmonary embolism; Reintervention for residual shunt/device removal; Sepsis; Stroke; Transient ischemic attack; Thrombus; Valvular regurgitation; Vascular access site injury; Vessel perforation

MAT-2010366 v1.0



© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.